Early prediction of immune checkpoint inhibitor treatment efficacy in patients with untreated advanced non-small-cell lung cancer
Not Applicable
- Conditions
- non-small cell lung cancer
- Registration Number
- JPRN-UMIN000037614
- Lead Sponsor
- Hokkaido University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 22
Inclusion Criteria
Not provided
Exclusion Criteria
1. Small-cell carcinoma or unknown 2. Positive for EGFR mutation, ALK fusion, Ros-1 fusion, and BRAF mutation 3. Ever treated with chemotherapy or radiotherapy 4. Poor physical status 5. Severe complication 6. Fasting blood glucose over 150 mg/dl 7. Unable to perform 18F-FDG PET/CT or CT because of complications 8. Other inappropriate patients
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To evaluate the discriminative power of the change of SUVmax, which is obtained via PET/CT 6 week after the initiation of pembrolizumab treatment.
- Secondary Outcome Measures
Name Time Method analysis using liquid biopsy